Literature DB >> 25823535

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Karim Chamie1, Pia Klöpfer2, Paul Bevan2, Stephan Störkel3, Jonathan Said4, Barbara Fall2, Arie S Belldegrun5, Allan J Pantuck5.   

Abstract

INTRODUCTION AND
OBJECTIVE: With a limited number of prognostic and predictive biomarkers available, carbonic anhydrase-IX (CAIX) has served as an important prognostic biomarker for patients with clear cell renal cell carcinoma (ccRCC). However, studies have recently called into question the role of CAIX as a biomarker for ccRCC. To investigate this uncertainty, we quantified the association of CAIX with lymphatic involvement and survival using data from ARISER study (WX-2007-03-HR)--a prospective trial involving subjects with high-risk nonmetastatic ccRCC. METHODS AND MATERIALS: We reviewed the records of 813 patients enrolled in the ARISER study. Central review of histology, grade, and CAIX staining (frequency and intensity) was performed. CAIX score was derived by multiplying the staining intensity (1-3) by percent positive cells (0%-100%), yielding a range of 0 to 300. We quantified the association of CAIX expression and score with lymphatic spread and survival (disease-free survival [DFS] and overall survival [OS]) using Kaplan-Meier and multivariable propensity score adjusted Cox regression analyses.
RESULTS: Median follow-up of the cohort was 54.2 months. Although 56% of subjects with lymphatic involvement had CAIX>85%, only 33% had CAIX score ≥ 200. On multivariable analysis, CAIX>85% was not a statistically significant predictor of DFS and OS (P = 0.06 and P = 0.15, respectively). However, CAIX score ≥ 200, when compared with CAIX score ≤ 100, was associated with improved DFS and OS (P = 0.01 and P = 0.01, respectively) on multivariable analysis.
CONCLUSIONS: The largest, multicenter, prospective analysis of patients with high-risk nonmetastatic ccRCC demonstrates the utility of CAIX score as a statistically significant prognostic biomarker for survival. We recommend that CAIX score be quantified for all patients with high-risk disease after nephrectomy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; CAIX; Clinical trial; Prognostic biomarker; Renal cell carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25823535     DOI: 10.1016/j.urolonc.2015.02.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  11 in total

1.  Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC.

Authors:  Lisa M Pickering; James Larkin
Journal:  Nat Rev Urol       Date:  2015-06-02       Impact factor: 14.432

Review 2.  Therapies targeting cancer stem cells: Current trends and future challenges.

Authors:  Denisa L Dragu; Laura G Necula; Coralia Bleotu; Carmen C Diaconu; Mihaela Chivu-Economescu
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

3.  KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study.

Authors:  Ghislaine Scelo; David C Muller; Elio Riboli; Mattias Johansson; Amanda J Cross; Paolo Vineis; Konstantinos K Tsilidis; Paul Brennan; Heiner Boeing; Petra H M Peeters; Roel C H Vermeulen; Kim Overvad; H Bas Bueno-de-Mesquita; Gianluca Severi; Vittorio Perduca; Marina Kvaskoff; Antonia Trichopoulou; Carlo La Vecchia; Anna Karakatsani; Domenico Palli; Sabina Sieri; Salvatore Panico; Elisabete Weiderpass; Torkjel M Sandanger; Therese H Nøst; Antonio Agudo; J Ramón Quirós; Miguel Rodríguez-Barranco; Maria-Dolores Chirlaque; Timothy J Key; Prateek Khanna; Joseph V Bonventre; Venkata S Sabbisetti; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

Review 4.  Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.

Authors:  Chris Blick; Alastair W S Ritchie; Timothy Eisen; Grant D Stewart
Journal:  Nat Rev Urol       Date:  2017-08-01       Impact factor: 14.432

5.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Authors:  Karim Chamie; Nicholas M Donin; Pia Klöpfer; Paul Bevan; Barbara Fall; Olaf Wilhelm; Stephan Störkel; Jonathan Said; Michael Gambla; Robert E Hawkins; Gustavo Jankilevich; Anil Kapoor; Evgeny Kopyltsov; Michael Staehler; Kimmo Taari; Alberto J A Wainstein; Allan J Pantuck; Arie S Belldegrun
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

Review 6.  Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.

Authors:  Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Claudiu T Supuran; Stefano Fais
Journal:  Metabolites       Date:  2017-12-23

Review 7.  Extracellular Vesicles in Renal Cell Carcinoma: Multifaceted Roles and Potential Applications Identified by Experimental and Computational Methods.

Authors:  Zhiyuan Qin; Qingwen Xu; Haihong Hu; Lushan Yu; Su Zeng
Journal:  Front Oncol       Date:  2020-05-07       Impact factor: 6.244

Review 8.  The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond.

Authors:  Silvia Pastorekova; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

9.  Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.

Authors:  Wataru Obara; Takashi Karashima; Kazuyoshi Takeda; Renpei Kato; Yoichiro Kato; Mitsugu Kanehira; Ryo Takata; Keiji Inoue; Toyomasa Katagiri; Taro Shuin; Yusuke Nakamura; Tomoaki Fujioka
Journal:  Cancer Immunol Immunother       Date:  2016-10-18       Impact factor: 6.968

Review 10.  Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.

Authors:  Joseph Lau; Kuo-Shyan Lin; François Bénard
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.